Group 1: Market Demand for Inorganic Iodides - The market for inorganic iodides is expected to grow significantly due to increasing demand in the pharmaceutical sector, driven by rising healthcare expenditures and an aging population [2] - The demand for contrast agents in medical imaging, particularly in oncology and cardiovascular diagnostics, is projected to increase, contributing to the expansion of the domestic contrast agent market [2] - The rapid development of the global pharmaceutical industry, especially in new drug research and development, is creating a broader market space for high-quality pharmaceutical intermediates, including inorganic iodides [2] Group 2: Applications in Electronics Manufacturing - The domestic production capacity of polarizers is increasing, with polarizers accounting for approximately 10% of the total cost of liquid crystal panels, where iodinated polarizers dominate with an 80%-90% market share [3] - Iodine and potassium iodide are essential raw materials for the production of iodinated polarizers, indicating a strong link between the electronics manufacturing sector and the demand for inorganic iodides [3] Group 3: Company Strategy and Talent Development - The company emphasizes talent development as a core competitive advantage, focusing on innovative recruitment and high-end talent acquisition to enhance overall competitiveness [3] - A dedicated training institution, referred to as the Future Academy, is established to improve employee skills and cultivate young talent, alongside partnerships with external consulting firms for customized training [3] Group 4: Trade Business and Customer Relations - The company's trade business primarily involves the export of refined iodine and other non-self-produced products, catering to the procurement needs of downstream pharmaceutical and chemical clients [3] - This business model not only meets diverse procurement needs but also strengthens strategic cooperation with clients, enhancing customer loyalty and business synergy [3]
博苑股份(301617) - 2025年5月29日投资者关系活动记录表